ALTAPURE

"DISINFECTION" CLAIMS BY THE UV-C AND PX-UV INDUSTRY CONSTITUTE DECEPTIVE ADVERTISING

I. Evidence Of The Deception

The three (3) examples shown below are just a few from sellers of UV-C and PX-UV light room treatment products who have, and are, committing **consumer deception** by falsely claiming that their products can "disinfect", "sterilize", or "decontaminate", when clearly, they **cannot**. The industry's assertions have been debunked by numerous independent peer-reviewed research papers, reported in key research journals, showing that UV room treatment systems do **not** meet the minimum Federal Government performance standards for Disinfection, Hospital Disinfection, and Sterilization. Even unsupported claims of Decontamination, are extremely serious and can impact the life, health, and safety, of the public as these claims are being relied by medical professionals to prevent injury and death.

Example # 1 – **Xenex**

https://www.xenex.com/about-xenex

Quote: "In use in more hospitals than any other **UV disinfection device**, Xenex offers the only **Pulsed Xenon UV disinfection system** on the market. Xenex Germ-Zapping Robots® are developed and designed to be highly effective, efficient and portable, allowing for the proven and **systematic disinfection of any space** within a healthcare facility." (*emphasis added*) (**11**)

Example # 2 - **Tru-D**

http://tru-d.com/benefits/

Quote: "Only Tru-D provides guaranteed, **total room disinfection** and has been validated by nearly all existing independent research on UVC room disinfection technology. As health care-associated infections continue to be a major threat to hospital reimbursements and the bottom line, hospital leaders must be diligent in choosing which technologies they invest in to help combat this serious problem. Proven consistent outcomes **provide a baseline of disinfection** that can only be accomplished with Tru-D's method of UVC dose measurement." (*emphasis added*) (**12**)

Example # 3 - **Surfacide**

http://www.surfacide.com/

Quote: "The Surfacide Helios system implements multiple emitters that allows us to **disinfect all areas** of the healthcare environments in a single cycle including the bathroom." (**13**)

Quote: "With Surfacide's three emitters operating during the same **disinfection cycle**, no exposed surface is left untouched." (*emphasis added*) (**13**)

The following is a recent example of a UV-C light product **not** meeting performance expectations at a Veterans Administration (VA) hospital in Ohio:

Quote: "The **number of C-Diff rooms has increased**, despite current sanitation procedures. The Louis Stokes Cleveland VA Medical Center **currently utilizes the Tru-D Smart UVC** Part Number: 0367AOLF, but we are **still not getting the desired results and the level of disinfection expected** to especially hard to reach areas." (*emphasis added*) (**1**) - **Louis Stokes VA Hospital**, Cleveland, OH, 2017, FedBizOpps Solicitation Number: VA250-17-Q-0774.

Contributing to the distribution of industry misinformation, paid industry authors have neglected to point out in their papers that UV light does **NOT** meet the EPA performance definition for a **Disinfectant** or a **Hospital-Disinfectant** and is **NOT** EPA or FDA approved as a **Sporicidal Product / Process** (ie: Clostridium difficile or C-diff.) for room treatment. Failing that, UV-C and PX-UV light products do **NOT Decontaminate** rooms. This entire industry has played fast and loose with their advertising claims**,** a luxury not afforded sellers of chemistry based products.

The Merriam-Webster dictionary defines the term "*decontaminate*" as: "to rid of contamination; to remove dirty or dangerous substances". UV light devices as used for room disinfection do **NOT** rid or remove dangerous pathogens, they may reduce some, **but they do not remove or eliminate pathogenic bio-burden even at 1.3 meters in the direct light beam and certainly not in an entire rooms as claimed.** The UV light room treatment industry also misuses this term.

The terms *Disinfection* and *Decontamination* have been specifically defined by the United States EPA and have specific mathematical and scientific meaning that have direct health and safety implications. These definitions have been relied upon by engineers, environmental cleaning people, and others within the scientific community, to insure that all of their processes are safe, efficacious, and/or meet Federal Regulations. The UV light room treatment industry has abused this system of relied upon scientific terms, by its use of the terms in advertising claims without ever meeting the EPA performance standards.

II. What Is Disinfection? And How Is the UV-C & PX-UV Industry Committing Deception ?

In general, in order to claim **disinfection** a cleaning process must attain at least a **6 Log reduction** of specific organisms, in a specified period of time. **Sterilization** means a complete kill of at least 6+ Log test material leaving **no growth** on any treated surfaces.

There are different United States Government standards for claiming surface **Disinfection** and **Sterilization**. The following is very brief summary – most are time dependent:

a) "General Disinfection" = **6 Log** reduction of "Staphylococcus aureus" **AND** "Salmonella enterica"
b) "Hospital Disinfection" = **6 Log** reduction of "Staphylococcus aureus" **AND** "Pseudomonas aeruginosa"
c) "Disinfectant with Fungicidal claims" = **6 Log** reduction of "Trichophyton mentagrophytes"
d) "Sterilant with C-Diff. Spore Claims" = **6 Log** reduction of "Clostridium difficile (C. difficile) spores"

See: OCSPP 810.2200 (3) (**2**), OCSPP 810.2200 (5) & (6) (**2**), OCSPP 810.2200 (9)(e) (**2**), and OCSPPP 810.2100 (d)(2) and (g) (**3**).

*** Note**: The full EPA standards are shown below in **Section VIII**.

The UV light room treatment industry should **NOT** be claiming the above performance standards unless their product(s) can meet or exceed each specific requirement. ***Deceptive advertising*** occurs when a claim is made, but where the product cannot actually meet the requirement(s).

III. UV light room treatment systems do NOT meet the above definitions as evidenced by the independent peer-reviewed research papers discussed below:

1) Michelle Nerandzic, and Curtis Donskey, MD et al.: "Evaluation Of An Automated Ultraviolet Radiation Device For Decontamination of Clostridium difficile and Other Healthcare-associated Pathogens In Hospital Rooms", BioMedCentral, BMC Infectious Diseases, **2010**, 10:197 . (**8**)



Figure 2 Mean reduction (log_{10} colony-forming units [CFU]/cm²) in recovery of multiple strains of *Clostridium difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Enterococcus* (VRE) from laboratory bench top surfaces after the use of the Tru-D device. For each pathogen, the inoculum applied to the bench top was adjusted such that 10^3 to 10^5 CFU were recovered from the positive control specimens. The Tru-D device was operated at a reflected dose of 22,000 μWs/cm² for ~45 minutes.

Comments – Figure 2: The **C. difficile** spore data in **Figure 2** above shows a *Log Reduction* range of (**2.2** to **3.1**) for direct UV-C light exposure for **45 minutes**.

Per Federal standards, if a test surface is contaminated with 1,000,000 bacteria, and a *Log Reduction* of about **2.2 Log** to **3.1 Log** is obtained for **C. difficile** spores by exposure to direct UV-C light, that means there will still be between about less than 1,000 to almost 10,000 **C. difficile** spore survivors remaining. This is **NOT** disinfection, decontamination, or sterilization**,** per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

The **MRSA (***Staphylococcus aureus***)** data in **Figure 2** above shows a *Log Reduction* range of (**2.8** to **3.4**) for direct UV-C light exposure.

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about **2.8 Log** to **3.4 Log** is shown for **MRSA** by exposure to direct UV-C light, that means there will still be between about more than 100 to more than 1,000 **MRSA** survivors remaining that can exponentially increase their population and constitute a health risk. This is **NOT** disinfection, decontamination, or sterilization**,** per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Conclusion: This study reinforces the currently reported research data that UV-C room treatment systems do **NOT** meet the legal definitions for disinfection, hospital disinfection, sterilization, or as a sporicidal against C. difficile, per the United States EPA and Federal regulations. (**2**)(**3**)

2) Jennifer L. Cadnum, and Curtis Donskey, MD, et al.: "Effect of Variation in Test methods on Performance of Ultraviolet-C Radiation Room Decontamination", Infection Control & Hospital Epidemiology, November **2016**. (**6**)



FIGURE 2. Effect of inoculum dispersal on killing of *Clostridium difficile* spores and methicillin-resistant *Staphylococcus aureus* (MRSA) by the Optimum-UV Device. Steel disk carriers were inoculated with 1×10^6 colony-forming units (CFU) of the pathogens in 10 µL of phosphate-buffered saline and the inoculum was either not spread (~4-mm^2 area on a 10-mm^2 disk), spread to cover the surface area of a 10-mm^2 disk, or spread to cover the surface area of a 22-mm^2 disk. The carriers were placed 4 feet from the device at a height of 4 feet and irradiated for 5, 10, 20, or 40 minutes. The means of data from triplicate experiments are presented. Error bars indicate standard error. Asterisk indicates $P < .01$ in comparison with the smaller surface area.

Comments – Figure 2: The data shown above in **Figure 2** is important, because it shows the *Log Reduction* data at **four (4) feet** after **ten (10) minutes** of UV-C exposure, for bacteria that were spread over different sized disks. The *Log Reduction* data only ranged from about (**0.6 - 2.0**) for **C. difficile** spores.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria spores, and a *Log Reduction* of about **0.6 Log** to **2.0 Log** is shown for **C. difficile** spores, between about 10,000 to 100,000+ **C. difficile** survivors will remain! This is **NOT** disinfection, decontamination, or sterilization. OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Also in **Figure 2**, the *Log Reduction* data ranged from about (**1.0 – 5.0**) for the **vegetative bacteria** (non-spore) **MRSA (***Staphylococcus aureus***)**, at four (4) feet after **ten (10) minutes** of UV-C exposure.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria, and a *Log Reduction* of about **1.0 Log** to **5.0 Log** is obtained for **MRSA (***Staphylococcus aureus***)**, that means there will still be between about 10 to 100,000 **MRSA** survivors remaining that can grow their population exponentially and infect people. This is **NOT** disinfection, decontamination, or sterilization. OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Comments – Figure 3: As shown below in **Figure 3**, the test media is exposed at **four (4) feet** for **ten (10) minutes** at different orientations to the UV-C light including at: zero (0) degree horizontal orientation, forty-five (45) degree orientation, and ninety (90) degree vertical orientation. The test results show *Log Reduction* data that ranged from only about (**1.3 - 2.2**) for **C. difficile** spores depending on the test orientation. The test results also showed *Log Reduction* data that ranged from only about (**3.3 – 4.8**) for **MRSA (***Staphylococcus aureus*) depending on the test orientation.

When a test surface is contaminated with 1,000,000 bacteria spores, and a *Log Reduction* of about **1.3 Log** to **2.2 Log** is shown for **C. difficile** spores, that means there will still be between about 1,000 to 10,000+ **C. difficile** survivors remaining. Pathogenic bio-burden is a health risk. When a *Log Reduction* of about **3.3 Log** to **4.8 Log** is obtained for **MRSA**, that means there will still be between about 10 to 100+ **MRSA** survivors remaining that can exponentially increase their population. This is **NOT** disinfection, decontamination, or sterilization, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

(Next Page)



FIGURE 3. Effect of orientation of the carriers relative to the ultraviolet-C lamps on killing of *Clostridium difficile* spores and methicillin-resistant *Staphylococcus aureus* (MRSA) by the Optimum-UV Device. Steel disk carriers were inoculated with 1×10^6 colony-forming units (CFU) of the pathogens in 10 µL of phosphate-buffered saline and the inoculum was spread to cover the entire 22-mm^2 surface area. The carriers were adhered to glass slides and positioned in parallel with the vertical lamp (ie, 90° vertical and directly facing the lamp), perpendicular to the lamp (ie, horizontal), or at a 45° angle from the lamp. The carriers were placed 4 feet from the device at a height of 4 feet and irradiated for 10 minutes. The means of data from triplicate experiments are presented. Error bars indicate standard error. Asterisk indicates $P < .01$ in comparison with the horizontal carriers.



FIGURE 1. Efficacy of the Tru-D versus Clorox Healthcare Optimum-UV System for killing of *Clostridium difficile* spores and methicillin-resistant *Staphylococcus aureus* (MRSA). Steel disk carriers were inoculated with 1×10^6 colony-forming units (CFU) of the pathogens in 10 µL of phosphate-buffered saline and the inoculum was spread to cover the 10-mm^2 surface area of the disk. The carriers were placed 4 feet from the devices at a height of 4 feet and irradiated for 5, 10, 20, or 40 minutes. The means of data from triplicate experiments are presented. Error bars indicate standard error.

Comments – Figure 1: The data shown above in **Figure 1** is important, because it shows the *Log Reduction* data at **four (4) feet** after **ten (10) minutes**, and also **forty (40) minutes**, of UV-C exposure, for the Tru-D UV-C product, and the Clorox Optimum UV-C product, for both **MRSA** bacteria and **C. difficile** spores.

The *Log Reduction* for **C. difficile** spores was about **1.7 Log** for Tru-D UV-C, and **1.6 Log** for Clorox UV-C, after **ten (10) minutes** of treatment.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria spores, a *Log Reduction* of about **1.7 Log** with Tru-D means there will be more than 10,000 **C. difficile** survivors remaining that can infect people, and a *Log Reduction* of about **1.6 Log** with Clorox Optimum UV-C means there will also be more than 10,000 **C. difficile** spores remaining that can infect people. This is **NOT** disinfection, decontamination, or sterilization, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

The *Log Reduction* for **C. difficile** spores was about **3.4 Log** for Tru-D UV-C, and **3.2 Log** for Clorox UV-C, after **forty (40) minutes** of treatment.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria spores, a *Log Reduction* of about **3.4 Log** with Tru-D means there will be more than 100+ **C. difficile** survivors remaining. A *Log Reduction* of about **3.2 Log** with Clorox Optimum UV-C means there will also be more than 100+ **C. difficile** spores remaining. This is **NOT** disinfection, decontamination, or sterilization, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Conclusion: First, this study demonstrates that even after **40 minutes**, both Tru-D's UV-C product, and Clorox's Optimum UV-C product, were still **NOT** able to reach a **6.0 Log** performance level for either **C. difficile or MRSA**, and neither of these products can claim disinfection, hospital disinfection, or sterilization, per Federal regulations. (**2**)(**3**)

This study also reinforces the previously reported research data that UV-C light surface treatment is adversely impacted by not only the exposure time to the UV-C light source, but also the orientation or angles of the surfaces to the UV light source.

More importantly, per the United States EPA, these independent data show that UV-C room treatment systems do **NOT** meet the legal definitions for disinfection, hospital disinfection, sterilization, or as a sporicidal against C. difficile, per Federal regulations. (**2**)(**3**)

3) William Rutala, PhD, MPH, and David Weber, MD, MPH et al.: "Room Decontamination with UV Radiation", Infection Control & Hospital Epidemiology, October **2010**, Vol. 31, No. 10. (**7**)

Quote: "The efficacy of UV irradiation is a function of many different location and operational factors, such as intensity, exposure time, lamp placement, and air movement patterns."

Quote: “In our test room, the effectiveness of UV-C radiation in reducing the counts of vegetative bacteria on surfaces was more than **99.9%** in approximately **15 minutes**, and the reduction in C. difficile spores was **99.8%** within **50 minutes**.”

Comment: According to Federal regulations, this is **NOT** disinfection, decontamination, or sterilization**,** that requires a **6.0 Log reduction** or *Percent Reduction* of **99.9999%**, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**) The **99.8% and 99.9%** reported percent reductions only equates to a *Log Reduction* of about **3.0 Log**, leaving viable organisms.

(Next Page)

TABLE 1. UV-C Decontamination of Formica Surfaces in Patient Rooms Experimentally Contaminated with Methicillin-Resistant *Staphylococcus aureus* (MRSA), Vancomycin-Resistant *Enterococcus* (VRE), Multidrug-Resistant (MDR) *Acinetobacter baumannii*, and *Clostridium difficile* Spores

		UV-C line of sight						
		Total		Direct		Indirect		
Organism	Inoculum	No. of samples	Decontamination, $\log_{10}$ reduction, mean (95% CI)	No. of samples	Decontamination, $\log_{10}$ reduction, mean (95% CI)	No. of samples	Decontamination, $\log_{10}$ reduction, mean (95% CI)	*P*
MRSA	4.88 $\log_{10}$	50	3.94 (2.54–5.34)	10	4.31 (3.13–5.50)	40	3.85 (2.44–5.25)	.06
VRE	4.40 $\log_{10}$	47	3.46 (2.16–4.81)	15	3.90 (2.99–4.81)	32	3.25 (1.97–4.62)	.003
MDR *A. baumannii*	4.64 $\log_{10}$	47	3.88 (2.59–5.16)	10	4.21 (3.27–5.15)	37	3.79 (2.47–5.10)	.07
C. difficile spores	4.12 $\log_{10}$	45	2.79 (1.20–4.37)	10	4.04 (3.71–4.37)	35	2.43 (1.46–3.40)	<.001

NOTE. Patient rooms had a mean area of 12.1 m^2 including bathroom. CI, confidence interval.

Comments – Table 1: The **C. difficile** spore data in **Table 1** above shows a *Log Reduction* range of (**3.71 to 4.37)** for direct UV-C light exposure, and (**1.46 to 3.40**) for indirect UV-C light exposure.

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about **3.71 Log** to **4.37 Log** is achieved for **C. difficile** spores with exposure to direct UV-C light, that means there will still be between about 10 to 100+ **C. difficile** spore survivors remaining on surfaces. This is **NOT** disinfection, decontamination, or sterilization**,** per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Also, if a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about **1.46 Log** to **3.40 Log** is achieved for **C. difficile** spores with exposure to indirect UV-C light, that means there will still be between about 100 to 10,000+ **C. difficile** spore survivors remaining on surfaces. This is **NOT** disinfection, decontamination, or sterilization**,** per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

The **MRSA (***Staphylococcus aureus***)** data in **Table 1** above shows a *Log Reduction* range of (**3.13** to **5.50**) for direct UV-C light exposure, and (**2.44** to **5.25**) for indirect UV-C light exposure.

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about **3.13 Log** to **5.50 Log** is achieved for **MRSA** with exposure to direct UV-C light, that means there will still be between about 1 to 100+ **MRSA** survivors remaining that can exponentially increase their population and infect a person. This is **NOT** disinfection, decontamination, or sterilization**,** per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about **2.44 Log** to **5.25 Log** is achieved for **MRSA** with exposure to indirect UV-C light, that means there will still be between about 1 to 1,000+ **MRSA** survivors remaining that can exponentially increase their population. This is **NOT** disinfection, decontamination, or sterilization**,** per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Conclusion: This study reinforces the current research data that UV-C light treatment process is adversely impacted by shadowed surfaces. More important, per the United States EPA and Federal regulations, this data shows that UV-C room treatment system results and claims do **NOT** meet the legal definitions for disinfection, hospital disinfection, sterilization, or as a sporicidal against C. difficile. (**2**)(**3**)

4) John M. Boyce, MD, et al.: "Impact of Room Location on UV-C Irradiance and UV-C Dosage and Antimicrobial Effect Delivered By A Mobile UV-C Light Device", Infection Control & Hospital Epidemiology, June **2016**, Vol. 37, NO. 6. (**5**)

Quote: "UV-C irradiance, UV-C dosage, and antimicrobial effect achieved in patient rooms varied significantly, depending on the location and orientation of surfaces relative to the UV-C device."

Quote: "With 15-minute cycles, counts of MRSA on disks were reduced by **3 to >4 log**10 and VRE by **1–4 log**10 at varying distances and orientations relative to the UV-C device (Table 2). **Log10 reductions of C. difficile** were highest (**2 to >4 log**10) when disks were facing the device at a distance of 1.3 m and were lowest (**0–1 log**10) when disks were in a shaded area 3.3 m from the device (Table 2)." (*emphasis added*)

Comments - Referring below, to **Table 2** and the data column for a 15 minute cycle (far right), the UV-C device was **NOT** able to achieve even close to a **6 Log** Reduction for **disinfection**, in direct light at even **1.3 meters**, for vegetative bacteria like MRSA, and VRE, as well as C. difficile spores. Instead, the UV-C product achieved a maximum performance of only around a >**4.0** Log Reduction. This is **NOT** disinfection, decontamination, or sterilization**,** as defined by the EPA. (**2**)(**3**)

However, more concerning was how the UV light performance was significantly degraded at even a short distance (1.3 meters) in situations where the MRSA, and VRE, as well as C. difficile spores, were exposed to the UV light at a zero (0) degree angle for a 15 minute cycle, providing a low *Log Reduction* range of only (**3.0 – 4.0**) for VRE, a low *Log Reduction* of only around >**4.0 Log** for MRSA, and a low *Log Reduction* range of only (**2.0 – 4.0**) for C. difficile!

TABLE 2. Range of Log_{10} Reductions of MRSA, VRE, and *Clostridium difficile* Achieved with Inoculated Disk Carriers Exposed to UV-C for 5-Minute and 15-Minute Cycles on 3 Occasions at Each Cycle Time

Distance and Orientation of Disks Relative to UV-C Device	Mean UV-C Dosage Measured Adjacent to Disks for 5-Min Cycles, µWsec/cm^2	Range of Log_{10} Reduction with 5-Min Cycles, by Pathogen	Mean UV-C Dosage Measured Adjacent to Disks for 15-Min Cycles, µWsec/cm^2	Range of Log_{10} Reduction with 15-Min Cycles, by Pathogen
1.3 m (4 ft), direct	342,667	MRSA: >4 log VRE: 4 to >4 log *C. difficile*: >2–3 log	842,000	MRSA: >4 log VRE: >4 log *C. difficile*: 2 to >4 log
1.3 m, 0° angle	53,900	MRSA: 4 to >4 log VRE: 3 to >4 log *C. difficile*: 1–2 log	148,667	MRSA: >4 log VRE: 3–4 log *C. difficile*: 2–4 log
1.3 m, shaded	8,547	MRSA: 1–4 log VRE: 2–3 log *C. difficile*: 0	24,467	MRSA: >4 log VRE: 2–3 log *C. difficile*: 1–2 log
3.3 m (10 ft), direct	67,567	MRSA: 4 to >4 log VRE: 3 to >4 log *C. difficile*: 1–3 log	202.667	MRSA: >4 log VRE: >4 log *C. difficile*: 2–4 log
3.3 m, 0° angle	10,767	MRSA: 4 to >4 log VRE: 2 log *C. difficile*: 0–1 log	29,000	MRSA: 4 to >4 log VRE: 3 log *C. difficile*: 0–2 log
3.3 m, shaded	3,395	MRSA: 1–3 log VRE: 1–2 log *C. difficile*: 0	8,880	MRSA: 3 log VRE: 1–2 log *C. difficile*: 0–1 log

MRSA, methicillin-resistant *Staphylococcus aureus*; VRE, vancomycin-resistant *Enterococcus*; UV-C, ultraviolet C.

*** NOTE**: *The data in **Table 2** represents the range of "Log Reduction" data for MRSA, VRE, and Clostridium difficile (C. Difficile) spores, where the innoculated disks were placed at six (6) different locations with respect to the UV-C device: direct light, angled light at zero (0) degrees, and shaded, at two (2) different distances: 1.3 meters (4 feet) and 3.3 meters (10 feet).*

Even more alarming regarding **Table 2** above, is how the UV light performance was significantly degraded at even a short distance (1.3 meters) in situations where the bacteria and spores were shaded from the UV light for a 15 minute cycle, providing an even lower *Log Reduction* range of only (**2.0 – 3.0**) for VRE, a low *Log Reduction* of only around >**4.0 Log** for MRSA, and an extremely low *Log Reduction* range of only (**1.0 – 2.0**) for C. difficile.

Finally, the UV light performance was very degraded at ten (10) feet or (3.3 meters) in situations where the bacteria and spores were shaded from the UV light providing an extremely low *Log Reduction* range of only (**1.0 – 2.0**) for VRE, a low *Log Reduction* of only around **3.0 Log** for MRSA, and a shockingly low *Log Reduction* range of only (**0 – 1.0**) for C. difficile! When exposed to the UV light at a zero (0) degree angle, for a 15 minute cycle, only a shockingly low *Log Reduction* range of (**0 – 2.0**) was achieved for C. difficile.

However, Cadnum and Dr. Donskey et al. (2016) (**6**), show that even a **40 minute exposure time** in the most favorable exposure orientation of facing the UV-C light (sold by Tru-D and Clorox), **at only 1.22 meters**, only provides a best case *Log Reduction* of about **5.3 Log** for the vegetative bacteria (non-spore) **MRSA (***Staphylococcus aureus***)**, and **an even worse best case *Log Reduction* of only 3.3 Log for C. difficle spores**. Obviously, after even 40 minutes of exposure, UV-C **cannot meet** the Federal standards for a **6.0 Log Reduction** to claim **Disinfection**, and UV-C **cannot** meet the Federal Standards of "no growth" to claim efficacy for **C. difficle** spores.

Conclusion: The various data shown above in **Table 2** and provided by Dr. Boyce et al. (2016), show that a UV-C light room treatment system is adversely impacted by surface angles, shadowing, and distance from the UV light source, and does **NOT** meet the legal definitions for disinfection, hospital disinfection, sterilization, or as a sporicidal against C. difficle, per Federal laws. (**2**)(**3**)

5) Michelle Nerandzic, and Curtis Donskey, MD et al.: "Evaluation of a Pulsed Xenon Ultraviolet Disinfection System for Reduction of Healthcare-Associated Pathogens in Hospital Rooms", Infection Control & Hospital Epidemiology, February 2015, Vol. 36 No 2. (**4**)

Quote: "As shown in Figure 3, **the efficacy of PX-UV decreased as distance from the device increased**. For each pathogen, significantly less reduction was achieved at 4 feet versus 6 inches and at 10 feet versus 4 feet (P < .05 for each comparison) .... At 10 feet from the device, the log 10 CFU reduction was less than 1 log 10 CFU/cm 2 for each pathogen." (emphasis added)

Quote: "The efficacy of PX-UV was dramatically reduced as the distance from the device was increased." (emphasis added)

*** Important Note**: PX-UV = Pulsed UV product, sold by **Xenex**



FIGURE 3. The effect of distance on the efficacy of the pulsed xenon ultraviolet (PX-UV) device.

The log_{10}CFU reduction/cm^2 of *Clostridium difficile* spores, methicillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Enterococcus* (VRE) at increasing distances and shaded from the direct field of radiation delivered by the PX-UV device is shown. Carriers contained 5 log_{10}CFU of each pathogen. The carriers were irradiated for 10 minutes at a distance of 6 in, 4 feet, 4 feet shaded, and 10 ft from the PX-UV device. The means of the data from experiments conducted in triplicate are presented. Error bars indicate standard error.

Comments – Figure 3: The data shown above in **Figure 3** is important, because it shows the *Log Reduction* data after **ten (10) minutes** of PX-UV exposure, for **MRSA** and **VRE** bacteria, and **C. difficile spores**, at the following distances and conditions: four (4) feet, four (4) feet (*and shaded*), and ten (10) feet. The *Log Reductions* are as follows:

4 ft.	10 minutes	C. difficile spores	**0.5**	Log Reduction (aprox.)
4 ft.	10 minutes (shaded)	C. difficile spores	**0.6**	Log Reduction (aprox.)
10 ft.	10 minutes	C. difficile spores	**0.2**	Log Reduction (aprox.)
4 ft.	10 minutes	MRSA	**1.8**	Log Reduction (aprox.)
4 ft.	10 minutes (shaded)	MRSA	**1.5**	Log Reduction (aprox.)
10 ft.	10 minutes	MRSA	**0.7**	Log Reduction (aprox.)
4 ft.	10 minutes	VRE	**0.6**	Log Reduction (aprox.)
4 ft.	10 minutes (shaded)	VRE	**0.4**	Log Reduction (aprox.)
10 ft.	10 minutes	VRE	**0.1**	Log Reduction (aprox.)

According to these data from **Figure 3**, the Xenex PX-UV light provided extremely low *Log Reductions*, and **NONE** of these *Log Reduction* values (C-diff. Spores and MRSA) are even close to meeting the Federal requirements to claim: disinfection, hospital disinfection, or sterilization, per the following EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**) The Xenex PX-UV light was **NOT** even able to achieve a *Log Reduction* anywhere close to the **5.0 Log** amount of inoculum applied to the test slides.

Also, the **Figure 3** data shows how drastically diminished the *Log Reduction* values were, when observed at a **distance of ten (10) feet from the UV light source**. The highest *Log Reduction* recorded was for **MRSA**, with a *Log Reduction* of only **0.7 Log**, which is no where even close to the **5.0 Log** amount of inoculum applied to the test slides, and certainly does **NOT** meet the EPA standards.

Comments – Figure 4: The data shown below in **Figure 4** shows the low *Log Reduction* performance for both the Xenex PX-UV light product, and the continuous mercury UV-C light product.

4 ft.	10 minutes	C. difficile spores	**1.0**	Log Reduction (aprox.) - UV-C
4 ft.	10 minutes	C. difficile spores	**0.5**	Log Reduction (aprox.) - Xenex, PX-UV
4 ft.	10 minutes	MRSA	**3.1**	Log Reduction (aprox.) - UV-C
4 ft.	10 minutes	MRSA	**1.8**	Log Reduction (aprox.) - Xenex, PX-UV
4 ft.	10 minutes	VRE	**3.6**	Log Reduction (aprox.) - UV-C
4 ft.	10 minutes	VRE	**0.6**	Log Reduction (aprox.) - Xenex, PX-UV



FIGURE 4. The efficacy of pulsed xenon ultraviolet (PX-UV) versus continuous mercury UV-C for killing of pathogens.
A comparison of the log_{10}CFU reduction/cm^2 of *Clostridium difficile* spores, methicillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Enterococcus* (VRE) by PX-UV and continuous mercury UV-C is shown. Carriers contained 5 log_{10}CFU of each pathogen. The carriers were irradiated for 10 minutes at a distance of 4 feet from the devices. The means of the data from experiments conducted in triplicate are presented. Error bars indicate standard error.

According to the data above from **Figure 4**, both the **Xenex PX-UV** light and the **continuous mercury UV-C** light product, **failed** to produce *Log Reduction* values (C-diff. spores and MRSA) that can satisfy the Federal requirements to claim: disinfection, hospital disinfection, or sterilization. OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

The data shown above in **Figure 4** is important, because it shows the poor *Log Reduction* data at **four (4) feet** after **ten (10) minutes** of PX-UV and UV-C light exposure. The *Log Reduction* data was reported at an extremely low *Log Reduction* of **0.5 Log** for **C. difficile** spores by the **Xenex PX-UV** product, and an extremely low *Low Reduction* of **1.0 Log** for **C. difficile** spores by the **continuous mercury UV-C** light product.

If a test surface is contaminated with 1,000,000 bacteria spores, and a *Log Reduction* of only **0.5 Log** is obtained by **Xenex PX-UV** for **C. difficile** spores, that means **more than 100,000+ C. difficile spore survivors will remain on the treated surfaces!** This is **NOT** disinfection, decontamination, or sterilization, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

In addition, the **Figure 4** data shows that when a test surface is contaminated with 1,000,000 bacteria spores, and a Log Reduction of **only 1.0 Log** for **UV-C light** is achieved for **C. difficile** spores, that means **100,000 C. difficile spores** will survive on the surface! This is **NOT** disinfection, decontamination, or sterilization, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (**2**)(**3**)

Conclusion: This study reinforces the previously reported research data that both the Xenex PX-UV light product, and the continuous mercury UV-C light product, are adversely impacted by the distance of the treated surfaces to the UV light source, and do **NOT** meet the EPA performance requirements for disinfection, hospital disinfection, sterilization, or as a sporicidal against C. difficile. (**2**)(**3**) Any claim of being able to "*disinfect an entire room*" flies in the face of this data.

6) Louis Stokes VA Hospital, Cleveland, OH, 2017, FedBizOpps, Solicitation Number: VA250-17-Q-0774

Quote: "The number of C-Diff rooms has increased, despite current sanitation procedures …. The Louis Stokes Cleveland VA Medical Center currently utilizes the **Tru-D Smart UVC** Part Number: 0367AOLF, but we are **still not getting the desired results and the level of disinfection** expected to especially hard to reach areas." (*emphasis added*) (**1**)

7) Irene Louh, MD, PhD, and Henry Ting, MD, et al.: "Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention", Infection Control & Hospital Epidemiology, April 2017, Vol. 38, NO. 4. (**10**)

Quote: "Terminal cleaning with **UV light *in addition* to bleach cleaning** had **uncertain efficacy**." (emphasis added)

Quote: "Haas et. al. instituted **pulsed UV treatment *in addition* to terminal bleach disinfection** in a large urban hospital, with **minimal incremental reduction in CDI rates**." (emphasis added)

8) U.S. CDC - Clinical Alert to U.S. Healthcare Facilities - June 2016, U.S. Centers For Disease Control & Prevention, "Global Emergence Of Invasive Infections Caused By The Multidrug-Resistant Yeast Candida auris", June 24, 2016 (last updated: **2017**). (**9**)

https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html

Quote: "The Centers for Disease Control and Prevention (CDC) has received reports from international healthcare facilities that Candida auris, an emerging multidrug-resistant (MDR) yeast, is causing invasive healthcare-associated infections with high mortality. Some strains of C. auris have elevated minimum inhibitory concentrations (MICs) to the three major classes of antifungals, severely limiting treatment options." (emphasis added)

Quote: "Environmental Cleaning – Anecdotal reports have suggested that C. auris may persist in the environment. Healthcare facilities who have patients with C. auris infection or colonization should ensure thorough daily and terminal cleaning and **disinfection of these patient's rooms** using an **EPA-registered hospital grade disinfectant** with a ***fungal claim***." (emphasis added)

Comment: The situation with **C. auris**, is a serious threat to human safety, and very specific standards are currently specified by the CDC, to address C. auris. UV-C and PX-UV are **NOT** mentioned by the CDC as an approved treatment to address the C. auris threat. Only *disinfectants* that can meet the United States EPA standards for **hospital disinfection** (OCSPP 810.2200 (5) & (6)), and **fungal claims** (OCSPP 810.2200 (9)(e)), are approved by the CDC to counter C. auris.

IV. Understanding Log Reduction Is Essential To Eliminating Pathogenic Risk

Hospital surfaces can be contaminated with many pathogenic bio-burden, and only achieving a *Log Reduction* at or below **6.0 Log** means dangerous viruses, bacteria, fungi, and C. difficile (C-diff) spores, can or will be left behind to proliferate and repopulate surfaces within the treated room. The literature has shown that bio-burden can be spread around to contaminate patients and/or grow new bacterial and fungal colonies on new surfaces. (**14**)

The number of bacterial survivors is very important because they can quickly increase their populations exponentially / logarithmically. For example, Staphylococcus aureus or (S. aureus) (under ideal conditions) doubles in 24-30 minutes (Generation Time, G), so this means 1,000 or 10^3 or *Log 3*, bacterial survivors would increase to 2,000 after 30 minutes, after 60 minutes they would increase to 4,000, and after two hours to 16,000 and then increase to over one million or 1,024,000 after 5 hours or more, if the growing environment is optimal.

V. Conclusion

The above cited data and references to the peer reviewed literature conclusively show that performance claims made by sellers of UV-C and PX-UV products go completely beyond marketing claims and hype, and constitute ***deceptive advertising***. In the "end of the antibiotic era" there is no room for deception when human lives are at stake.

VI. Images Showing Deceptive Advertising

1) **Xenex – Example # 1 -** https://www.xenex.com/about-xenex



2) **Xenex - Example # 2 -** https://www.xenex.com/



3) **Xenex - Example # 3 -** https://www.xenex.com/frequently-asked-questions



Comment: The claim of “deactivation” of endospores is without meaning in the scientific literature and by the the definitions used by the EPA. Where is the working definition of the term “deactivation” and what does that mean in terms of kill performance, disinfection, and sporicidal (C. difficile) claims, especially as it pertains to hospitals and the EPA?

4) **Tru-D - Example # 1 -** http://tru-d.com/

(Next Page)

5) **Tru-D - Example # 2 -** http://tru-d.com/benefits/

Tru-D's Unmatched Validation Says it Best.

Only Tru-D provides guaranteed, total room disinfection and has been validated by nearly all existing independent research on UVC room disinfection technology. As health care-associated infections continue to be a major threat to hospital reimbursements and the bottom line, hospital leaders must be diligent in choosing which technologies they invest in to help combat this serious problem. Proven consistent outcomes provide a baseline of disinfection that can only be accomplished with Tru-D's method of UVC dose measurement.

6) **Tru-D - Example # 3 -** http://tru-d.com/about-tru-d/faq/#1456947876200-f36808c5-a7fc



Comment: The claims shown in the above examples, that Tru-D's UV light can somehow *disinfect* "shadowed" surfaces is not logical since a shadowing effect on surfaces in the room is caused by objects obstructing or blocking the UV light that is depended upon to achieve the efficacy of their process.

A claim of killing pathogens in the "shadowed areas" constitutes a false and misleading advertising and is in conflict with the published literature. (**4, 5**)

7) **Surfacide - Example # 1 -** http://www.surfacide.com/

The Next Generation UV-C Disinfection

Surfacide provides an evidence-based, automated UV-C hard surface disinfection system that data indicate eradicates multi-drug resistant organisms including C.diff, MRSA, VRE, CRE and Acinetobacter. Our approach is different. The Surfacide Helios system implements multiple emitters that allows us to disinfect all areas of the healthcare environments in a single cycle including the bathroom.

8) **Surfacide - Example # 2 -** http://www.surfacide.com/



Real Problems are Shadows, Distance & Time/Labor

Overcoming Shadows

UV-C is a direct line of sight technology. Single emitter systems, (including pulsed xenon gas systems) simply cannot reach all high touch surfaces in a single disinfection cycle. Relying upon reflected energy to measure, analyze, and determine the proper dose of UV energy is flawed. With Surfacide's three emitters operating during the same disinfection cycle, no exposed surface is left untouched.

(Next Page)

9) **Terra Universal - Example # 1**

https://www.terrauniversal.com/cleaning-systems/torch-portable-uv-disinfection-clordisys.php



Comment: The claim of disinfection does not meet the EPA performance definition. A 99% kill still leaves a large residue of viable pathogens. The claim of killing C. difficile at ten feet, and in one minute, is in direct conflict with papers published by Drs., Boyce, Rutala and Donskey. The claim of "room disinfection" is not only misleading but not supported by any published paper to date. To make such a claim one would have to define the room size and sample all the surfaces including: walls, floor, ceiling, and all the equipment surfaces, in the room.

The claim of eliminating pathogens located in shadowed areas using multiple devices is misleading, since this cannot be easily proved or relied upon in real world applications, and especially when considering various human factors that can make reproducibility difficult to maintain. This is extremely important to consider when human life or health can be put in jeopardy when these devices, and their processes of use, are being relied upon.

10) **Terra Universal - Example # 2**

https://www.terrauniversal.com/laminar-flow-hoods/uv-sterilization-v-ray-01.php



Comment: Note that the claim of a 99+ kill does not meet the EPA definition of either disinfection or sterilization. This claim is both false and misleading. Further, the statements do not tell the user what distance from the source is required or how long the organism must be exposed. Surface shadowing is also not addressed and its risks are not discussed.

(Next Page)

11) **ClorDiSys Solutions, Inc. - Example # 1**

http://www.clordisys.com/torch.php

Comment: In order to claim sterilization, the data would have to meet the the EPA standard stated in OCSPP 810.2100 (g). To ensure patient and staff safety all products claiming sterilization must meet the same requirement. Disinfection claims are also made.

(Next Page)

12) ClorDiSys Solutions, Inc. - Example # 2

http://www.clordisys.com/pdfs/misc/Torch%20Data%20Sheet.pdf

Exposure Time Required for Given log Reduction of Various Organisms		Distance (ft)							
		2	3	4	5	10	15	20	25
		Intensity (mJ/(cm²*min))							
Organism/Reduction	Required dose (mJ/cm²)	102	61.5	48.8	37.8	12.7	4.8	2.58	1.86
C. diff		Exposure Time (min)							
! → 2 log	15.5	0.15	0.25	0.32	0.41	1.22	3.23	6.01	8.33
! → 3 log	22	0.22	0.36	0.45	0.58	1.74	4.58	8.53	11.8
B. subtilis spores									
! — 2 log	39	0.38	0.63	0.8	1.03	3.08	8.13	15.1	21
! — 3 log	60	0.59	0.98	1.23	1.59	4.74	12.5	23.3	32.3
S. aureus									
! — 2 log	5.4	0.05	0.09	0.11	0.14	0.43	1.13	2.09	2.9
! — 3 log	6.5	0.06	0.11	0.13	0.17	0.51	1.35	2.52	3.49
E. coli									
— 2 log	6	0.06	0.1	0.12	0.16	0.47	1.25	2.33	3.23
— 3 log	9	0.09	0.15	0.18	0.24	0.71	1.88	3.49	4.84

Comment: Note that the data shows results that do not even come close to the OCSPP 810.2100 performance standards as mandated by the United States EPA.

13) Fuller Ultraviolet Mobile Room Sterilizers

http://www.fulleruv.com/mobile.html

"Fuller *Ultraviolet* Mobile *Room Sterilizers* are self-contained, UVC irradiators that can be placed just about anywhere. Mounted on casters, these units are ideal… (emphasis added)

Comment: A claim of sterilization is the highest level of kill and should meet the EPA performance test standard: OCSPP 810.2100.

VII. Log Reduction Reference

Log Reduction	Number of cfu's	Percent Reduction
0 log (Log 0)	1,000,000	0%
1 log (Log 1)	100,000	90%
2 log (Log 2)	10,000	99%
3 log (Log 3)	1,000	99.9%
4 log (Log 4)	100	99.99%
5 log (Log 5)	10	99.999%
6 log (Log 6)	1	99.9999%

VIII. UNITED STATES FEDERAL DEFINITIONS FOR "DISINFECTANTS", "HOSPITAL DISINFECTANTS", AND "STERILANTS"

a) US Legal Definition for "General Disinfection / Broad Spectrum Efficacy"

Reference: OCSPP 810.2200 (3)

DEFINITION: General or broad spectrum efficacy products - When a disinfectant is represented in labeling as having efficacy against both Gram-negative and Gram-positive bacteria, the product is considered a "*general or broad spectrum*" disinfectant.

According to the United States Environmental Protection Agency (EPA), "*Disinfection*" is defined as set forth in EPA Product Performance Test Guidelines, OCSPP 810.2200.

The test microorganisms are:

1) Effective against **both** Gram-negative **and** Gram-positive bacteria.
2) Staphylococcus aureus (S. aureus)(ATCC 6538) for effectiveness against Gram-positive bacteria.
3) Salmonella enterica (ATCC 10708) (S. enterica) for effectiveness against Gram-negative bacteria.

The test criteria states:

"Evaluation of confirmatory general or broad spectrum disinfectant success. *The product should kill all the test microorganisms on all carriers in ≤ten minutes*. In addition, per the 2009 AOAC revisions for the Use-Dilution Method, the mean log density for S. aureus is to be at least 6.0 (corresponding to a geometric mean density of 1.0 x 10^6); *a mean log density <6.0 invalidates the test. For the Hard Surface Carrier Test, the dried carrier counts should be 0.5 –2.0 x 10^6 for Salmonella enterica and 1 – 5 x 10^6 for Staphylococcus aureus*." (emphasis added) (**2**)

*** Summary:** To meet the definition of "General Disinfection" a ***6 log kill*** has to be obtained for both "Staph" and "Salmonella" in less than 10 minutes.

---

b) US Legal Definition for "Hospital Disinfection"

Reference: OCSPP 810.2200 (5) & (6)

The EPA has a specific category established for the hospital and healthcare markets. For these markets, the following efficacy is required to meet the definition of disinfection as set forth in EPA Product Performance Test Guidelines, OCSPP 810.2200.

The test microorganisms are:

1) Effective against **both** Gram-negative **and** Gram-positive bacteria.
2) Staphylococcus aureus (S. aureus)(ATCC 6538) for effectiveness against Gram-positive bacteria.
3) Pseudomonas aeruginosa (P. aeruginosa)(ATCC 15442) for effectiveness against Gram-negative bacteria.

The test criteria states:

"Evaluation of confirmatory hospital or healthcare disinfectant success. *The product should kill all the test microorganisms on all carriers in ≤ten minutes*. *In addition, per the 2009 AOAC revisions for the* Use-Dilution Method, the mean log density for S. aureus and P. aeruginosa is to be at least 6.0 (corresponding to a geometric mean density of 1.0 x 10^6); a mean log density <6.0 invalidates the test. For the Hard Surface Carrier Test, the dried carrier counts should be 1 –5 x 10^6 for both Staphylococcus aureus and Pseudomonas aeruginosa." (emphasis added) (**2**)

*** Summary:** To meet the definition of "Hospital Disinfection" a ***6 log kill*** has to be obtained for both "Staph" and "Pseudomonas" in less than 10 minutes.

---

c) US Legal Definition for "Disinfectants With Fungicidal Claims"

Reference: OCSPP 810.2200 (9)(e)

The test microorganism is:

1) Trichophyton mentagrophytes (T.mentagrophytes)(ATCC 9533)

Two samples representing two different batches of the product should be evaluated for efficacy against Trichophyton mentagrophytes (T. mentagrophytes)(ATCC 9533). The inoculum employed should provide a concentration of ≥*5 x 10^6* conidia/mL.

Evaluation of fungicidal success. For the AOAC International Fungicidal Activity of Disinfectants test, all fungal spores at 10 and 15 minutes should be killed to support a 10 minute exposure time. For the AOAC International Use-Dilution Methods, ***all*** *fungal spores on all 10 carriers should be killed in ≤ten minutes*. (emphasis added) (**2**)

---

d) US Legal Definition for "Sterilant w/ Clostridium difficile Claims"

Reference: OCSPPP 810.2100 (d)(2) and (g)

General Liquid Sterilants Claims - Mandated Log Reductions:

5-6 Log reduction minimum for BOTH Bacillus subtilis (B. subtilis) spores and Clostridium sporogenes (C. sporogenes) spores, AND must reach at least **6 Log** reduction minimum for Clostridium difficile (C. difficile) spores, to be classed as liquid Sterilant w/ Clostridium difficile (C. difficile) Claims. Kill everything, **no growth**, on ALL slides in less than XX minutes (time not specified).

The test microorganisms are:

1) Effective against: (B. subtilis) **and** (C. sporogenes) **and** (C. difficile)
2) Clostridium difficile (C. difficile) (ATCC 700792), (ATCC 43598) or (ATCC 43599)
3) Bacillus subtilis (B. subtilis) (ATCC 19659)
4) Clostridium sporogenes (C. sporogenes) (ATCC 3584)

Evaluation of sterilant success. *The inoculum employed should provide a count of 1 x 10^5 – 1 x 10^6 spores per carrier*. The product should kill the test spores *on all 120 carriers without any failures* (e.g., growth of test organism after carrier treatment constitutes failure). (**3**)

IX. REFERENCES

1) **Louis Stokes Cleveland**, 2017, FedBizOpps Solicitation Number: VA250-17-Q-0774, FedBizOpps

2) **United States Govt.**, https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0150-0021

3) **United States Govt.**, https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0150-0020

4) **Michelle Nerandzic, and Curtis Donskey, MD et al**.: *"Evaluation of a Pulsed Xenon Ultraviolet Disinfection System for Reduction of Healthcare-Associated Pathogens in Hospital Rooms"*, Infection Control & Hospital Epidemiology, February **2015**, Vol. 36 No 2.

5) **John M. Boyce, MD, et al.**: "*Impact of Room Location on UV-C Irradiance and UV-C Dosage and Antimicrobial Effect Delivered By A Mobile UV-C Light Device*", Infection Control & Hospital Epidemiology, June **2016**, Vol. 37, NO. 6.

6) **Jennifer Cadnum, and Curtis Donskey, MD, et al**.: "*Effect of Variation in Test methods on Performance of Ultraviolet-C Radiation Room Decontamination*", Infection Control & Hospital Epidemiology, November **2016**.

7) **William Rutala, PhD, MPH, and David Weber, MD, MPH et al**.: "*Room Decontamination with UV Radiation"*, Infection Control & Hospital Epidemiology, October **2010**, Vol. 31, No. 10.

8) **Michelle Nerandzic, and Curtis Donskey, MD et al**.: "*Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms*", BioMedCentral, BMC Infectious Diseases, **2010**, 10:197.

9) **U.S. CDC - Clinical Alert to U.S. Healthcare Facilities - June 2016**, U.S. Centers For Disease Control & Prevention, "*Global Emergence Of Invasive Infections Caused By The Multidrug-Resistant Yeast Candida auris"*, June 24, 2016 (last updated: **2017**).

10) **Irene Louh, MD, PhD, and Henry Ting, MD, et al.**: "*Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention*", Infection Control & Hospital Epidemiology, April **2017**, Vol. 38, NO. 4.

11) **Xenex** - https://www.xenex.com/about-xenex

12) **Tru-D** - http://tru-d.com/benefits/

13) **Surfacide** - http://www.surfacide.com/

14) Sreelatha Koganti, MD, and Curtis Donskey, MD - "Evalution of Hospital Floors as a Potential Source of Pathogen Dissemination Using a Nonpathogenic Virus as a Surrogate Marker", Infection Control & Hospital Epidemiology, November 2016, Vol. 37, No. 11.

